Medtronic Upgrade Sends Shares Up 5.1% After Q2 Beat
Is the Medtronic Upgrade the start of a bigger rerating, or just a brief earnings-fueled spike?
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical…
| Quarter | Revenue | YoY | Net Income | EPS (dil.) | YoY | Gross Margin | Op. Margin |
|---|---|---|---|---|---|---|---|
| Q 2026 Apr 2026 | $9.81B | — | $1.24B | $0.96 | — | 65.4% | 20.5% |
| Q 2026 Jan 2026 | $9.02B | — | $1.14B | $0.89 | — | 63.8% | 17.8% |
| Q 2025 Oct 2025 | $8.96B | — | $1.37B | $1.07 | — | 65.8% | 18.9% |
| Q 2025 Jul 2025 | $8.58B | — | $1.04B | $0.81 | — | 65.0% | 17.7% |
| Q 2025 Apr 2025 | $8.93B | — | $1.06B | $0.82 | — | 64.8% | 20.1% |
Data from Yahoo Finance. YoY compares the same quarter of the prior fiscal year.
Is the Medtronic Upgrade the start of a bigger rerating, or just a brief earnings-fueled spike?